Chemotherapy After Progression on Maintenance Olaparib in BRCA-Mutated Platinum-Sensitive Ovarian Cancer
A post-hoc analysis of the SOLO2 trial investigated the efficacy of chemotherapy after progression while on maintenance olaparib versus placebo in patients with platinum-sensitive ovarian cancer and found chemotherapy to be less efficacious in patients who received maintenance olaparib versus placebo.
This network meta-analysis comparing first-line maintenance therapies in advanced ovarian cancer revealed that PARP inhibitors result in better outcomes than antiangiogenic agents. Individual PARP inhibitors vary in efficacy and adverse events across mutation subtypes.
Results from the GEICO1601-ROLANDO Phase 2 Trial Evaluating Combination of Olaparib and PLD in Platinum-Resistant Ovarian Cancer
In patients with platinum-resistant ovarian cancer, 46% treated per protocol with olaparib and pegylated liposomal doxorubicin (PLD) achieved 6-month progression-free survival regardless of BRCA status. Adverse events were less frequent with a reduction of the PLD dose.
Results of 5-Year Follow-Up of Maintenance Olaparib in Patients with Newly Diagnosed, Advanced Ovarian Cancer
The SOLO1 trial studied maintenance olaparib in newly diagnosed patients with advanced BRCA-mutated ovarian cancer. This analysis assesses outcomes 5 years after the last patient enrolled in the trial and represents the longest follow-up for a PARP inhibitor trial in this setting.
Olaparib + Durvalumab and Bevacizumab: Initial Results in Patients with Non-Germline BRCA-Mutated Platinum-Sensitive Relapsed Ovarian Cancer
For patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer, the triple combination of olaparib, durvalumab, and bevacizumab demonstrated a promising 24-week disease control rate and safety profile while the combination of olaparib plus durvalumab did not meet the prespecified efficacy target.
The VIRO-15 trial of intraperitoneal Olvi-Vec virus infusion followed by intravenous carboplatin-doublet ± bevacizumab in pretreated platinum-resistant/refractory ovarian cancer patients revealed promising response rates and progression-free survival. Safety results were consistent with a previous phase 1b trial of this agent.
Efficacy and Safety of Niraparib in Older Patients with Advanced Ovarian Cancer from PRIMA/ENGOT-OV26/GOG-3012
In patients with advanced ovarian cancer, niraparib resulted in similar efficacy, safety, and quality-of-life outcomes for patients 65 years of age and those ≥65 years of age. An individualized starting dose resulted in fewer grade ≥3 thrombocytopenia events than a fixed starting dose.
Olaparib Maintenance Therapy in Clinical Practice: Quality-of-Life Interim Results of the C-PATROL Study in Ovarian Cancer
An observational study of hospitalized patients and patients in outpatient treatment facilities being treated with olaparib as maintenance therapy for relapsed BRCA-mutated ovarian cancer following platinum-based chemotherapy reveals preservation of health-related quality of life in interim study results.
Response to Olaparib Monotherapy in Relapsed Ovarian Cancer by HRR Gene Mutational Status and HRD Scarring Analysis
A phase 2, randomized study of patients with platinum-resistant relapsed ovarian cancer assessed overall response to olaparib monotherapy compared with standard-of-care chemotherapy. Olaparib was effective in platinum-resistant and platinum-sensitive patients with and without homologous recombination repair (HRR) gene alterations.
Timing of Adverse Events During Maintenance Treatment with Rucaparib for Recurrent Ovarian Cancer in Phase 3 Study
The phase 3 ARIEL3 study investigated rucaparib as maintenance therapy in patients with recurrent ovarian cancer. An exploratory safety analysis found time to onset of nonhematologic treatment-emergent adverse events was 1 month, 2 months for anemia, and 3 months for decreased hemoglobin.
Page 2 of 3
Results 11 - 20 of 21
Results 11 - 20 of 21